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Tissue engineered vascular grafts (TEVGs) are useful in the surgical treatment of
congenital heart defects. The development of TEVGs requires seeding of scaffolds
composed of biodegradable polymers with bone marrow-derived mononuclear cells (BMMNCs). The most common method used to isolate BM-MNCs involves density
centrifugation in Ficoll. This process requires an International Organization for
Standardization (ISO) class 7 clean room, is labor intensive, time intensive, and
susceptible to operator variability. A recently developed filtration-based method for BMMNC isolation uses a closed, sterile, and disposable system that removes the need for a
clean room, decreases processing time, and is operator-independent. This study
compared the efficacy of each method of BM-MNC isolation by evaluating the viability
of cells recovered using each method, and by assessing the biologic and structure
equivalence between neo-vessels created from scaffolds seeded using cells isolated by
either method.

BM-MNCs were isolated from the bone marrow of immunocompetent syngeneic
C57BL/6 wild type mice by either density centrifugation in Ficoll or using a filter-based

method. The cells were seeded onto scaffolds fabricated from a polyglycolic acid (PGA)
mesh coated with a 50:50 copolymer sealant of poly-L-lactide-co-ε-caprolactone. Seeded
scaffolds were incubated overnight and then implanted as inferior vena cava (IVC)
interposition grafts in 10-week-old wild type mice (n = 23 for each group). Grafts were
explanted at 2 weeks post-implantation for analysis.

Significantly greater total (filter: 44.3 ± 12.6x106 cells/mouse versus density
centrifugation: 24.8 ± 8.8x106 cells/mouse, p=0.02) and viable (filter: 32.8 ± 6.7x106
cells/mouse versus density centrifugation: 20.6 ± 8.7x106 cells/mouse, p=0.04) BMMNCs were isolated using filtration versus density centrifugation-based isolation. There
was no significant difference in graft patency (filter: 78% patency versus density
centrifugation: 87% patency, p=0.7), luminal diameter (filter: 633 ± 131 μm versus
density centrifugation: 620 ± 82.9 μm, p=0.72) or neointimal thickness (filter: 37.9 ± 11.2
μm versus density centrifugation: 37.9 ± 7.8 μm, p=0.99) between groups at explantation.
There was also no significant difference in quantitative macrophage infiltration between
the two methods at explantation (filter: 1887 ± 907.7 cells/mm2 versus density
centrifugation: 2041 ± 1078 cells/mm2, p=0.59).

BM-MNCs isolated using density centrifugation or the filter-based method were
biologically equivalent and TEVGs formed from scaffolds seeded by each method were
structurally similar when examined up to 14-days post-implantation in our in vivo murine
model.
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LIST OF ABBREVIATIONS

α -SMA – alpha smooth muscle actin
BMC – bone marrow cell
BM-MNC – bone marrow-derived mononuclear cell
cDNA – complementary deoxyribonucleic acid
cGMP- current Good Manufacturing Practice
CHD – congenital heart disease
CMV – cytomegalovirus
CT – computed tomography
Ct – cycle threshold
CTA – computed tomography angiography
DNA – deoxyribonucleic acid
ePTFE – expanded polytetrafluoroethylene
EVG – elastica van Gieson
FACS – fluorescence-activated cell sorting
FDA – Food and Drug Administration
H&E – hematoxylin and eosin
hBM-MNC – human bone marrow-derived mononuclear cell
HLA – human leukocyte antigen
HPRT – hypoxanthine phosphoribosyltransferase
INR – International Normalized Ratio
ISO – International Organization for Standardization
IVC – inferior vena cava
LRF – leukocyte reduction filter
MCP-1 – monocyte chemotactic protein 1
MMP-2 – matrix metalloproteinase-2
MRI – magnetic resonance imaging
OCT – optimal cutting temperature
P(CL/LA) – poly (ɛ)-caprolactone and L-lactide copolymer
PBS – phosphate-buffered solution
PET – polyethelene terephthalate (Dacron)
PGA – polyglycolic acid
PLA –polylactic acid
PLLA – poly-L-lactic acid
PTFE – polytetrafluoroethylene
qPCR – quantitative polymerase chain reaction
RNA – ribonucleic acid
RPMI-1640 – Roswell Park Memorial Institute medium
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SCID/bg – scid/scid, beige/beige double-mutant mouse strain
SEM – scanning electron microgram
TEVG – tissue engineered vascular graft
VEGF – vascular endothelial growth factor
vWF – von Willebrand factor
WHO – World Health Organization
YARC – Yale Animal Resource Center
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INTRODUCTION

The field of vascular tissue engineering is driven by the demand for durable vascular
conduits that mirror the performance of native blood vessels. One important limitation in
this process is the time required to create a viable neo-vessel. At first, tissue engineered
scaffolds were seeded in vitro and incubated for several weeks to allow for the
development of a vascular architecture prior to implantation. For the next generation of
tissue engineered grafts, scaffolds were seeded and incubated in vitro for several hours
before being implanted and allowed to transform into a viable vessel in vivo. In the
current study, we strive to decrease the time and labor required to isolate the cells used
for seeding. If this process can be streamlined appropriately then the entire process from
obtaining cells to seeding the scaffold and implanting the graft into a patient can all occur
during the intraoperative time frame of one operation. To understand this process, some
background is required.

In the United States, congenital heart disease (CHD) affects approximately 1% of live
births. Most infants born with a single functional ventricle, which include those with
hypoplastic left heart syndrome, pulmonary atresia or tricuspid atresia, require surgical
treatment to prevent cyanosis, volume overload, and congestive heart failure. The goal of
surgical correction is to separate systemic circulation from pulmonary circulation to
prevent the mixing of deoxygenated and oxygenated blood.
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This correction is most often accomplished through a staged Fontan operative procedure
in which systemic venous blood returning to the right heart is instead routed directly to
the pulmonary artery, bypassing the single functional ventricle. Following passage
through the lungs, the oxygenated blood returns to the single functional ventricle through
the pulmonary veins and is pumped in normal fashion into the aorta to deliver oxygen to
tissues1. The Fontan procedure is conducted in two separate stages. During the first stage
of the Fontan procedure, the superior vena cava is connected to the pulmonary artery,
thereby decreasing the workload of the single ventricle. However, these patients often
display significant hypoxia because deoxygenated blood carried by the inferior vena cava
(IVC) continues to return directly to the single ventricle where it mixes with oxygenated
blood returning from the lungs. Therefore, most patients undergo the second stage of the
Fontan procedure, which connects the IVC to the pulmonary artery and allows all
deoxygenated blood to bypass the heart and flow directly to the lungs. However, because
the IVC is not adjacent to the pulmonary artery, this distance is bridged by placing a
vascular conduit between the IVC and the pulmonary vasculature.

Types of grafts:
Currently, grafts are most often composed of biocompatible, but synthetic, polymers
including polyethylene terephthalate (PET, Dacron), expanded-polytetrafluoroethylene
(ePTFE, Gore-Tex), polytetrafluoroethylene (PTFE, Teflon) and polyurethanes2. These
synthetic polymers, however, are associated with a number of short and long-term
complications that most notably include stenosis, thromboembolism, calcium deposition,
and infection3,4. Furthermore, the 5-year patency rate in pediatric cardiac surgery for
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these procedures remains between 65% and 90% while long-term follow-up
demonstrated high graft failure with between 70% and 100% failing at 10-15 years5.

In addition to synthetic grafts, biologic grafts may be used. These grafts are crafted using
autologous tissues, including saphenous vein and pericardium, allografts, and
xenografts6. Biologic grafts have lower rates of thromboembolism than synthetic grafts.
However, they also have increased rates of calcification, graft failure, and
pseudoaneurysm formation compared with synthetic grafts7,8. Most significantly,
however, none of these graft material options have the ability grow with the patient.
Since pediatric patients often outgrow surgically implanted grafts, patients with such a
surgical scenario require reoperation9. Such redo procedures are reported to have
significantly higher mortality and morbidity than initial sternotomies10.

Any new graft material should address the limitations of both synthetic and biologic
grafts to reduce the overall mortality and morbidity in patients with CHD and improve
their postoperative quality of life. The ideal vascular graft would be easily implantable
with ease of handling during surgery, have low levels of stenosis, low rates of
thromboembolism, high growth potential, and be resistant to infection.

Scaffolds:
The goal of tissue engineering is to provide materials that incorporate into and function
similarly to the patient’s native tissue thus allowing normal physiologic function. This is
accomplished using scaffolds that function as a surface for cell attachment and growth
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followed by new tissue formation on the scaffold. To promote the creation of functional
tissue, the scaffolds must resemble the desired tissue in both size and shape11. The
formation of new tissue is followed by degradation of the original scaffold leaving a fully
functional neo-vessel composed solely of autologous tissue. Pluri- or multipotent stem
cells are often used in the process to create these tissue engineered vascular grafts
(TEVGs) (Figure 1).

A successful TEVG scaffold material should have the following three characteristics: 1)
be biodegradable, 2) be anti-thrombotic, and 3) have adequate porosity and pore size to
allow for cell attachment12. The most common polymers used for tissue engineered
scaffolds include variations of polyglycolic acid (PGA) and polylactic acid (PLA) used in
conjunction with poly (ɛ)-caprolactone13,14.

Some researchers have developed TEVGs using decellularized allogeneic human or
xenogenic porcine vessels seeded with autologous endothelial cells from the recipient15.
However, allo- or xenotransplantation carries the risk of developing an immunologic
response with subsequent destruction of the graft. Choosing the correct material is
essential for the creation of TEVGs that will adequately remodel into a viable neovessel.
Several important factors include biocompatablity, mechanical properties, and the
biodegradation profile.

It is important to note that TEVGs have rigidity. Their lumen does not collapse when
implanted in vivo due to the biomechanical properties of the scaffolds. The tensile
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strength of PGA with a 50:50 copolymer sealant solution of poly-(ε)-caprolactone and Llactide (P(CL/LA)) is approximately twice the tensile strength of native venous tissue16.
In addition, the suture retention strength of PGA-P(CL/LA) scaffolds are greater than the
corresponding values for native veins17. Further, the resultant burst pressure of PGAP(CL/LA) scaffolds under increasing pneumatic pressure is significantly greater than the
physiologic burst pressure for native veins18. Finally, the intrinsic elasticity of PGAP(CL/LA) scaffolds, measured using Young’s modulus, indicates that these scaffolds are
more elastic than synthetic ePTFE grafts but stiffer than native venous tissue18-20.
Young’s modulus is defined as the ratio of stress (force per unit area) along an axis to the
strain (ratio of deformation from initial length) along the same axis21.

TEVGs have a rich history with initial development in the early 90s of highly porous
biocompatible scaffolds cultured with smooth muscle22. Subsequently, TEVGs
constructed using autologous myofibroblasts and endothelial cells seeded in vitro onto
PGA fiber scaffolds were surgically implanted into lambs. These were the first studies to
successfully create viable vascular conduits in a large animal model23. In this lamb
model, venous cells were harvested from explanted autologous vein and expanded in cell
culture. These cultured cells were labeled with acetylated low-density lipoprotein that is
selectively absorbed by endothelial cells. Following an additional 24-hours of incubation,
cells were sorted into endothelial cell (low-density lipoprotein positive) or smooth muscle
cell and fibroblast (low-density lipoprotein negative) populations. These two populations
of cells were then seeded onto PGA scaffolds. The scaffold was maintained in culture for
seven days after which the endothelial-rich population from the original cell culture was
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seeded onto the inner lumen. This scaffold was maintained in culture for an additional
day. When harvested six months after implantation, all seeded scaffolds remained patent
and free of aneurysm formation, and histology showed significant collagen formation,
elastic fiber content, and endothelialization of the lumen23.

Scaffold seeding:
The previously described method of seeding TEVGs was successful and firmly
established the feasibility of using TEVGs for the surgical treatment of congenital heart
defects. However, the widespread clinical utility of this process was severely limited by
the labor intensive process of obtaining the precursor cells and the prolonged time period
needed to adequately expand the cells in culture before they could be used for scaffold
seeding.

In search of a more efficient method of seeding biodegradable scaffolds Noishiki et al.
had noted that grafts seeded with bone marrow cells (BMCs) would release autocrine
molecules leading to the formation of a luminal endothelial monolayer in a canine aortic
model24. The early development of a luminal endothelium is important because it
prevents the formation of acute thrombosis and subsequent graft occlusion. However,
because they had used a synthetic, non-biodegradable ePTFE scaffold in their
experiment, Matsumura et al. decided to test the feasibility of creating viable TEVGs
using biodegradable scaffolds seeded with the more easily obtained BMCs25. In this
experiment, bone marrow was aspirated from the iliac crest of dogs and bone marrowderived mononuclear cells (BM-MNCs) were isolated using density centrifugation. These
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cells were seeded onto the luminal surface of a poly-L-lactic acid (PLLA)-P(CL/LA)
scaffold and incubated in culture for two hours to promote cell adhesion. The scaffolds
were implanted as intrathoracic IVC interposition grafts and harvested over a period of
two years. For an interposition graft, a segment of the native vessel is removed and
replaced with the TEVG. The two ends are reconnected (anastomosed) using sutures.
Over the course of the experiment, all seeded grafts remained patent without evidence of
aneurysm formation, thrombosis or stenosis. Pre-implantation analysis demonstrated
retention and adherence of BM-MNCs to the scaffold and immunohistochemical analysis
of explanted tissue was positive for luminal endothelial markers (von Willebrand factor
(vWF), factor VIII, CD31 and CD146), medial smooth muscle markers (SM1, SM2,
SMemb, and α-actin), and markers of angiogenesis (vascular endothelial growth factor
(VEGF) and Ang-1)25. This study illustrated that autologous BM-MNCs could be used to
create viable TEVGs with several benefits over using cells from explanted venous tissue.
First, obtaining venous cells from explanted tissue requires an invasive procedure with
numerous risks, especially wound complications such as dehiscence, prolonged drainage,
cellulitis, and hematoma formation26. Second, cells cannot always be obtained from
explanted tissue and this is affected by the patient’s comorbidities and age due to the
limited capacity of adult somatic cells to replicate27. Third, the expansion of cells from
explanted tissue takes weeks and severely limits the usefulness of this method in clinical
settings. Fourth, the prolonged exposure of the cells to environmental factors from the
culture media, pathogens, and even autologous molecules increases the risk of
contamination or cellular dedifferentiation. BM-MNCs overcome these issues by
eliminating the need for invasive harvesting techniques and prolonged cell-line
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expansion. This in turn limits the risk of bacterial contamination and mitigates decreases
in cellular viability and function.

Clinical studies:
The first human clinical trial using TEVGs to treat children with CHD was started at
Tokyo Women’s Medical University in April 1999. For the first three patients in the trial,
venous cells were obtained through vein harvesting, expansion in ex vivo cell culture and
followed by incubation of the seeded scaffolds. In 2001, the method of scaffold seeding
was changed first to direct bone marrow seeding and finally to seeding using BM-MNCs
as based on the results described above28-30. Scaffolds seeded with BM-MNCs were
incubated preoperatively for two to four hours before implantation. In 2005, at midterm
follow-up of 42 patients who underwent surgery between 2001 and 2004, with average
time since operation of 1.3 years, there were no graft related complications. This included
no aneurysm formation, ectopic calcification, acute thrombosis, stenosis, or graft
occlusion. While all grafts remained patent at time of analysis, the diameter of the grafts
had increased on average to 110 ± 7% of their original size. One patient with hypoplastic
left heart syndrome had died of complications unrelated to TEVG function 3 months
following operation27.

At long-term follow up of 25 patients with implanted grafts with average time from
operation of 5.8 years, there was no graft-related mortality, graft infection, ectopic
calcification, graft failure, or aneurysm formation. Three patients had died of causes
unrelated to TEVG function and serial cineangiography or computed tomography (CT)
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taken prior to death showed patent grafts31. This is in sharp contrast to outcomes in
patients undergoing Fontan procedures using synthetic grafts. In a study of 193 patients
undergoing extracardiac Fontan procedures, overall freedom from graft failure was 89%
at five years and 85% at 10 years. At 15 years, 6.7% of surviving patients had developed
thrombosis with 3% presenting with significant obstruction diagnosed during Doppler
echocardiography. At 15 years, cumulative freedom from cavopulmonary pathway
obstruction was 89%3. In a study of 200 patients at 10-year follow-up, reoperation was
performed in 12% of patients and thromboembolism occurred in 6.5% of patients with
84.6% of these occurring within one year of their operation32. Patients in the TEVG study
received three to six months of anticoagulation with warfarin and aspirin (INRInternational Normalized Ratio recommended between 1.5 and 2). From six to 12
months, patients were maintained on aspirin alone after which time anticoagulation was
discontinued28. Patients with synthetic grafts, in contrast, often remained on antiaggregation therapy indefinitely3,33.

TEVG growth potential:
As discussed earlier, one of the main advantages of using TEVGs in the pediatric
population is their ability to grow with the child. To characterize and evaluate the growth
potential of TEVGs, Brennan et al. implanted PGA grafts into a juvenile lamb model34. It
is important to note that each animal model has specific characteristics that make it ideal
for the evaluation of certain biological processes. In pediatric patients undergoing
corrective surgery for congenital heart disease, ectopic calcification is a leading cause of
graft failure23. Importantly, lamb vasculature undergoes accelerated ectopic calcification
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during growth as compared to other large animal models such as pigs and dogs35. The
juvenile lamb study demonstrated patent TEVGs at six months with no evidence of
rupture, thromboembolism or significant ectopic calcification. Serial magnetic resonance
imaging (MRI) showed an increase in TEVG size proportional to the unaltered right
pulmonary artery (control). Quantitative analysis revealed the volume of TEVGs at six
months averaged 126.9 ± 9.9% of their volume at one month and that wall thickness was
comparable between the TEVG and native IVC (control). At six months, histological
analysis demonstrated that the implanted TEVGs and native vein had comparable
amounts of elastin, collagen and glycosaminoglycan. Immunohistochemistry revealed
endothelialization of the lumen with surrounding layers of smooth muscle cells.
Importantly, this was the first study to demonstrate expression of Eph-B4 in TEVGs,
which is a marker of venous differentiation expressed during native venous tissue
growth34. This finding suggests that TEVG remodeling resembles normal venous
development.

Promising results from the aforementioned studies and improvements in the efficiency of
creating and seeding TEVGs led to the 2009 Food and Drug Administration (FDA)
approval at Yale of a US clinical trial of TEVGs in pediatric patients with single ventricle
cardiac anomalies.

Small animal models:
Large animal models are an essential step in providing important data on the safety and
efficacy of TEVGs that can be readily translated to human clinical trials. However, these
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models are less ideal for analyzing the molecular and cellular mechanisms responsible for
graft remodeling and for elucidating the processes involved in the development of
neovessels. Mice are an ideal organism for studying the biologic development of
cardiovascular tissue due to their short generation time, accelerated lifespan, and the
homology between human and murine genes responsible for numerous complex genetic
pathologies such as atherosclerosis36,37. One major limitation for using a murine model
was developing a functional scaffold with a sub-1 mm internal diameter that could then
be implanted using microsurgical techniques. The development of the first smalldiameter biodegradable scaffold was reported in 2008 by Roh et al18. They developed a
dual cylinder system that allowed nonwoven felts of PGA to be shaped into tubes during
insertion into the dual cylinder chamber. Next, 21 gauge stainless steel rods were
introduced into the lumen of the scaffolds before application of a 50:50 copolymer
sealant solution of P(CL/LA) to prevent collapse of the scaffold inner lumen. The
resulting tubes were rapidly frozen to transform the P(CL/LA) sealant from the liquid to
the solid phase leading to a solid, non-collapsing porous scaffold. Scanning electron
microgram (SEM) revealed an internal diameter of 0.9 mm with a wall thickness of 150
μm18. Of note, current synthetic materials such as PTFE or PET (Dacron) cannot be used
to create clinically functional grafts with sub-1 mm internal diameters38.

Density centrifugation versus filter collection:
At this juncture, our group had developed viable animal models to characterize the
molecular development of neo-vessels and had shown the effectiveness of BM-MNCs in
this process numerous times. However, several important limitations remained as
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obstacles to the widespread clinical application of TEVGs. Currently, BM-MNCs are
generally isolated from bone marrow using density centrifugation with Ficoll, a soluble
high-mass polysaccharide used to facilitate the separation of blood into its components39.
Lower density mononuclear cells and platelets collect on top of the Ficoll layer, while
higher density erythrocytes and granulocytes collect below the Ficoll layer. Subsequent
centrifugation and washing of the top layer with phosphate-buffered saline (PBS) can be
used to separate mononuclear cells from platelets40. There are, however, several
drawbacks to using Ficoll density gradient centrifugation to isolate BM-MNCs. First,
erythrocytes may form aggregates with mononuclear cells causing unwanted
sedimentation of the mononuclear cells into the bottom layer. Second, repeated and
prolonged handling of the sample may decrease viability of isolated cells. Third, cellular
damage may cause cell aggregation leading to decreased yield of mononuclear cells41.
Fourth, density centrifugation is affected by operator proficiency leading to significant
variability42. Fifth, Ficoll isolation uses an open method that exposes the sample to the
environment during isolation. In clinical practice, an open system must use an
International Organization for Standardization (ISO) class 7 clean room to limit the risk
of bacterial contamination and meet the standard of current Good Manufacturing Practice
(cGMP). These clean rooms are expensive to construct and maintain in compliance with
sterile production standards. They also require substantial human resources to operate43.

If a sterile disposable blood filter could be integrated into a closed system of collection, it
would not require a clean room, would be operator-independent, would decrease the risk
of contamination, would reduce cellular damage and facilitate the clinical use of TEVGs.
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The World Health Organization (WHO) defines a closed system as the aseptic collection
and separation of blood components under clean conditions sealed from the external
environment44. In this system, bone marrow can be transferred directly into a sterile
plastic holding chamber using a syringe. The bone marrow is filtered by gravity-mediated
downward longitudinal flow and mononuclear cells are captured on a nonwoven
polyester fiber filter media by interception. The trapped BM-MNCs are recovered by
back-flushing the filter and reversing the direction of flow through the closed system.
This filter was originally adapted from leukocyte reduction filter-based systems (LRF)
used by blood banks to facilitate the isolation of white blood cells from blood products.
Use of this blood filter in clinical transfusion practice helps expedite the removal of some
cell associated viruses (CMV-cytomegalovirus) and decrease human leukocyte antigen
(HLA) alloimmunization, which in turn decrease transfusion reactions, infections and
febrile episodes45.

The ability of a filter-based method to effectively isolate mononuclear cells was
illustrated by Hibino et al when they successfully isolated MNCs from human bone
marrow (hBM-MNCs)46. They subsequently seeded PGA-P(CL/LA) with hBM-MNCs
isolated using either the traditional density centrifugation with Ficoll method or using the
experimental filter-based method. These seeded scaffolds were implanted as IVC
interposition grafts in immunocompromised SCID/bg mice. These mice have impaired
lymphoid development and reduced natural killer cell activity which prevents host
rejection of the implanted human cells47. It took significantly less time for cell isolation
by filtration (10 ± 12 min) compared to density centrifugation (106 ± 11 min). Despite
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this, there was no significant difference in the number of hBM-MNCs isolated by either
method. Fluorescence-activated cell sorting (FACS) showed that the percentage of viable
cells and the ratio of stem cells to mononuclear cells were comparable between both
groups. Analysis of TEVG histology at 10 weeks post-implantation revealed no
difference between scaffolds seeded by either method. Both graft groups demonstrated an
endothelial monolayer as evidenced by positive luminal vWF staining. Positive alpha
smooth muscle actin (α-SMA) and calponin staining demonstrated the formation of a
smooth muscle layer in both groups. Serial monitoring by ultrasonography, CT
angiography (CTA) and post-explant analysis revealed no aneurysm formation or graft
rupture over 10 weeks in both groups.

This technique was subsequently used to create TEVGs that were effectively implanted
into a large animal model48. Specifically, bone marrow was obtained from lambs and
BM-MNCs were isolated using an open system density centrifugation method or a closed
system filter-based method. PGA-P(CL/LA) scaffolds were seeded with cells isolated
using either method and implanted into juvenile lambs as intrathoracic IVC interposition
grafts. Results demonstrated that total procedure time from removal of bone marrow to
insertion of graft was significantly less using the closed system (2 hrs 17 min) compared
to the open method (4 hrs 28 min). Further, there was no significant difference in the
number of cells seeded onto scaffolds in either group. Two animals in the open method
group developed significant graft stenosis requiring early sacrifice, while all six lambs in
the closed method group survived without any evidence of graft related complications
including acute thrombosis, stenosis, or aneurysm formation. Histologic analysis of tissue
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explanted six months after implantation demonstrated that the cellular architecture in
both groups mirrored native vein (control) with the development of three distinct layers
including an intimia, media and adventitia48.

Current thesis research:
At this stage, it had been shown that scaffolds seeded with BM-MNCs isolated via a
closed filter-based system could develop viable TEVGs that resembled native tissue in
immunocompromised mice46. However, we needed to show that this was possible in
immunocompetent mice. Therefore, to compare the effectiveness of the novel filter-based
collection method with the conventional density centrifugation technique using Ficoll, we
isolated BM-MNCs from the bone marrow of wild type, immunocompetent C57BL/6
mice using the two methods. Then we seeded biodegradable scaffolds with the isolated
BM-MNCs and implanted them as IVC interposition grafts into the same strain of mice.
We hypothesized that neo-tissue formed from the biodegradable scaffolds seeded using
BM-MNCs isolated from each method would be biologically, structurally, and
functionally equivalent.
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METHODS AND MATERIALS

Scaffolds:
A 50:50 fiber mesh constructed with a poly-glycolic acid coated with copolymer sealant
solution of poly-L-lactide-co-ε-caprolactone was used for scaffold construction18,49.
Scaffolds were 4 mm long with a diameter of 0.9 mm.

Bone marrow-mononuclear cell preparation and scaffold seeding:
BM-MNCs were extracted from the bone marrow of immunocompetent CB57BL/6 wild
type mice through two distinct methods, specifically, density centrifugation using Ficoll
versus filtration. For the filtration method, BM-MNCs were isolated from bone marrow
as follows: 5 mL of bone marrow was extracted from a minimum of five mice and the
resulting volume was increased to 15 mL by adding RPMI 1640. Using a syringe, this
mixture was transferred to a sterile storage chamber that was connected to a scaled down
version of the commercially available polyester fiber human blood cell filter. This filter
functions to capture BM-MNCs in the filter media through interception, thus retaining the
needed cells. The filters were washed twice with PBS to remove entrapped and unwanted
erythrocytes from the filter. The BM-MNCs that were retained in the filter were isolated
by reverse-flushing the filter with 6 mL of 10% dextran 40/saline solution. This solution
was centrifuged and the resulting pellet was diluted using RPMI-1640 (Figure 2)48. For
Ficoll density centrifugation, bone marrow was extracted and centrifuged at 400 g for 30
min in Histopaque-1083. The low density layer containing monocytes was removed and
transferred into a new tube. This was washed with PBS and centrifuged at 100 g for 10
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min. The supernatant was removed and fresh PBS was added to the resulting pellet. This
pellet was centrifuged for a third time at 100 g for 10 min. The supernatant was again
removed and the isolated BM-MNCs were suspended in RPMI 164049. For scaffold
seeding, 1.0x106 BM-MNCs isolated using either method were seeded onto the luminal
graft surface manually using a pipet. The seeded scaffolds were placed in 1 mL of sterile
RPMI-1640 in a CO2 incubator for 24 hours at 37 oC to promote adherence of BM-MNCs
to the scaffold49.

Seeded scaffold cell counts:
Following BM-MNC isolation using the density centrifugation and filter methods,
manual cell counts were performed for each group. In addition, cell viability was
assessed using trypan blue staining also followed by manual cell counting. The
deoxyribonucleic acid (DNA) content of seeded scaffolds following 24 hour incubation
was obtained using a PicoGreen DNA detection assay42.

Surgical implantation into murine model:
Animals were treated appropriately as required by the National Institutes of Health Guide
for the Care of, and the Yale University policy on, Use of Laboratory Animals. The Yale
Institutional Animal Care and Use Committee approved the use of animals and
procedures for this study. All mice were 10-week-old ‘wild type’ C57BL/6 mice
purchased from Jackson Laboratories.
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TEVGs were implanted as IVC grafts by members of our lab in CB57BL/6 mice with n =
23 for each group, group 1 (density centrifugation) and group 2 (filter), using standard
microsurgical technique as follows: All mice were anesthetized with an intraperitoneal
injection of 0.10 ketamine/xylazine mixture. A midline laparotomy incision from the
xyphoid to the suprapubic region was made and the intestines were wrapped in salinemoistened gauze to approach the inferior vena cava. Microvascular clamps were used to
clamp the IVC followed by transection of the vessel. The interposition graft was
introduced and secured using end-to-end anastomoses with sutures. Heparinized solution
was used frequently to prevent formation of an acute thrombosis18,49. Mice were kept in
regularly cleaned and maintained cages by the Yale Animal Resource Center (YARC)
where they were fed ad libitum. All mice were sacrificed 14-days following implantation
and grafts were explanted following saline perfusion of the circulatory system.

Ultrasound monitoring of implanted TEVGs:
At 3, 7, and 14-days post-implantation graft luminal diameter was determined using
ultrasonography and graft patency was determined by assessing flow velocity both
proximal and distal to the graft using Doppler ultrasonography. To perform
ultrasonography on mice, 1.5% isoflurane was used as an anesthetic.

Histology:
Following graft explantation at 14-days, grafts were fixed using 4% para-formaldehyde,
embedded in paraffin, sliced into 5 μm sections, and mounted onto slides. These sections
were stained using Hematoxylin and Eosin (H&E), Alcian Blue (mucins), von Kossa
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(calcium), Masson’s trichrome (collagen), and Elastica van Gieson (EVG) (elastin). On
H&E stained specimens, the intima, media, and adventitia were identified and measured
manually using ZEN lite, and post-explantation graft patency was defined as a luminal
diameter greater that 50% compared to the graft diameter prior to implantation.

Immunohistochemistry:
Paraffin embedded sections of explanted graft, created as described above, were stained
with anti-vWF, anti-SMA, anti-matrix metalloproteinase-2 (MMP-2) and anti-F4/80
antibodies to identify murine endothelial cells, smooth muscle cells, MMP-2 and
macrophages respectively. Anti-iNOS and anti-CD206 antibodies were used to identify
M1 and M2 macrophage phenotypes respectively. Biotinylated IgG was used to detect
primary antibody attachment. This was followed by streptavidin-horse radish peroxidase
binding and color development, which was accomplished using 3,3-diaminobenzidine.

Macrophage quantification:
Macrophages were identified using F4/80 expression as described above. Each stained
graft section was dived into eight regions and stained macrophage nuclei were counted
manually in three of the eight regions at 400x magnification.

Ribonucleic acid (RNA) extraction real time-quantitative polymerase chain reaction:
Grafts explanted following 14-days of implantation were embedded in optimal cutting
temperature (OCT) compound and rapidly frozen in a -80 oC freezer. These frozen grafts
were sliced into twenty 30 μm sections and total RNA was extracted and purified using a
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Qiagen RNeasy mini kit according to the manufacturer’s instructions. Reverse
transcription was performed using an Applied Biosystems high capacity RNA-to-cDNA
kit. Quantitative polymerase chain reaction (qPCR) was performed using a Step One Plus
Real-Time PCR system using a TaqMan Universal PCR Master mix Kit with the
following primers and reference numbers: CCR2 (Mm00438270_m1), itgam
(Mm00434455_m1), ym1 (Mm00657889_mH), and HPRT (Mm00446968_m1) as a
control. In real-time qPCR, gene replication is detected by an increase in fluorescent
signaling and cycle threshold (Ct) is defined by the number of replication cycles required
to surpass a predefined threshold (which is based on a background level of gene
expression). Therefore, Ct levels are inversely proportional to the amount of target
messenger RNA in the sample. Relative quantification compares the change in expression
of the target gene in the TEVG from native IVC in relation to the change in expression of
an endogenous reference gene, hypoxanthine phosphoribosyltransferase (HPRT),
between the TEVG and native IVC. This is referred to as the comparative cycle threshold
method and results as reported as ΔΔ Ct which describes the change in expression of the
target gene in the TEVG compared to expression in control native IVC50.

Statistical analysis:
Based on results by Hibino et al. in 2011, a patency rate of 70% in grafts seeded with
density centrifugation isolated BM-MNCs versus 30% in unseeded grafts at 14-days postimplantation was assumed51. Based on these data, sample size was calculated using
Fisher’s exact probability test using an alpha-error of 0.05 and a power of 0.8.
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All numerical values are listed as the mean ± 1 standard deviation and the sample size is
also included. Statistical significance was determined as a P value < 0.05. The Student’s t
test was used for continuous variables with normal distribution while the Welch’s t test
was used for two groups with unequal variance (substantially different standard
deviations). Continuous variables with non-normal distribution were evaluated using the
nonparametric Mann-Whitney test. Dichotomous variables were evaluated using the
Fisher’s exact test.
Procedure

Involvement

Scaffold construction and seeding

Primary

BM-MNC isolation

Primary

Seeded scaffold cell counting

Primary

Surgical implantation of scaffolds

Assistant to Tai Yi and Hirotsugu Kurobe

TEVG ultrasound monitoring

Primary

Histology preparation

Yale Histology and Histomorphometry Laboratory

Histology analysis

Primary

Immunohistochemistry

Primary

Macrophage quantification

Primary

RNA extraction and RT-qPCR

Primary

Statistical analysis

Primary

Table 1. Involvement with specific procedures conducted during the course of this
experiment. The author had primary involvement with all aspects of the experiment except
surgical implantation of scaffolds in the murine model and with preparation of histology slides.
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RESULTS

Comparison of BM-MNC isolation:
Both total BM-MNC and viable BM-MNC counts following filtration were significantly
greater than those seen following density centrifugation-based cell isolation (total cells,
filter: 44.3 ± 12.6x106 cells/mouse versus density centrifugation: 24.8 ± 8.8x106
cells/mouse, p=0.02; viable cells, filter: 32.8 ± 6.7x106 cells/mouse versus density
centrifugation: 20.6 ± 8.7x106 cells/mouse, p=0.04; Figure 3). The filter-based BM-MNC
isolation method also showed significantly greater cell attachment following 24-hour
scaffold incubation as detected by PicoGreen DNA assay evaluation of scaffold DNA
content between the two groups (filter: 15.5 ± 6.3x103/mm2 versus density centrifugation:
12.4 ± 2.5x103/mm2, p=0.04; Figure 4).

TEVG monitoring via ultrasound:
Serial ultrasonographic evaluation on day 3, 7, and 14 showed no significant difference in
luminal diameter of graft patency between the filtration and density centrifugation
methods. In both groups, the graft patency and the luminal diameter decreased with each
time point. However, no aneurysm formation, hemorrhagic complications, thrombus
formation or embolization was detected in either group.

Evaluation of graft patency and luminal diameter:
There was no statistically significant difference in graft patency between the two groups
as determined using H&E stained slides of grafts explanted following 2 weeks of
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implantation (filter: 78% patency versus density centrifugation: 87% patency, p=0.7;
Figure 5A). Manual measurement of patent grafts did not show any statistically
significant difference in neointimal thickness (filter: 37.9 ± 11.2 μm versus density
centrifugation: 37.9 ± 7.8 μm, p=0.99) or lumen diameter (filter: 633 ± 131 μm versus
density centrifugation: 620 ± 82.9 μm, p=0.72) (Figure 5B).

TEVG histology:
Neovessel formation, cellular infiltration into the TEVG, cellular distribution in the
TEVG, and cellular architecture appeared similar between the two groups (filter and
density centrifugation) using H&E staining of grafts explanted after 2 weeks of
implantation. Both groups demonstrated abundant collagen deposition within TEVGs as
evidenced by Alcian blue and Masson’s trichrome extracellular matrix stains. Elastica
van Gieson stain demonstrated a paucity of elastin in both groups, while the absence of
von Kossa staining demonstrated lack of graft calcification in either group. Of note,
unabsorbed poly-glycolic acid fibers resulted in non-specific staining by both von Kossa
and Alcian blue stain, and they resemble capillaries or vacuoles on H&E stain.

TEVG immunohistochemistry:
SMA immunohistochemical staining of smooth muscle cells was found mainly in the
media of explanted TEVGs of both groups. vWF staining was used to identify the
luminal intima of TEVGs in each group and it demonstrated endothelialization of the
explanted tissue. Matrix metalloproteinase-2 is a central component for effective
remodeling of seeded scaffolds into neovessels and previous studies have shown that
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MMP-2 activity is greatest two weeks post-implantation in mice52. In our results, MMP-2
staining showed similar activity in grafts explanted from both groups at 14 days postimplantation.

TEVG macrophage analysis:
Abundant F4/80 immunohistochemical staining in TEVGs demonstrated that infiltration
by macrophages occurred in both groups. There did not appear to be any difference in
infiltration by the two major macrophage phenotypes, M1 and M2, in TEVGs seeded
using either method of cell isolation. There was no statistically significant difference in
quantitative macrophage infiltration between the number of F4/80 positive cells between
the two groups (filter: 1887 ± 907.7 cells/mm2 versus density centrifugation: 2041 ± 1078
cells/mm2, p=0.59; Figure 6). Variation in macrophage phenotype, M1 (filter: 0.82 ± 0.67
versus density centrifugation: 1.00 ± 0.99, p=0.67) and M2 (filter: 1.26 ± 1.30 versus
density centrifugation: 0.92 ± 0.67, p=0.52) , between the two groups was assessed using
qPCR in explanted grafts and no statistically significant difference was found (Figure 7).
Macrophage gene expression as determined by qPCR using the monocyte marker CD11b
demonstrated no statistical significance between the two groups at the following time
points: following isolation but prior to seeding (filter: 1.38 ± 0.68 versus density
centrifugation: 1.00 ± 0.60, p=0.16) and following explantation at 2 weeks (filter: 1.03 ±
0.71 versus density centrifugation: 1.00 ± 0.55, p=0.97) (Figure 7).
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DISCUSSION

The goal of our study was to assess the difference between BM-MNCs isolated using a
conventional density centrifugation in Ficoll method versus a unique filter-based method.
Furthermore, we analyzed the effect of each method on neo-vessel formation and
remodeling of implanted scaffolds, using an immunocompetent murine model.

We found no difference in luminal diameter, graft patency, or incidence of stenosis
between grafts created using scaffolds seeded by either method. There was also no
difference between the histologic or immunohistochemical structure of neo-tissue with
regard to intima, media, and adventitia formation, location of collagen deposition,
endothelial cell attachment, smooth muscle infiltration or graft calcification. A previous
study had shown differences in macrophage phenotype in isolated BM-MNCs based on
method of bone marrow filtration46. However, we found no difference in macrophage
phenotype both following bone marrow isolation and in grafts, explanted after two weeks
of implantation. Further, macrophage polarization and amount of infiltration was similar
in grafts seeded by either method.

These findings are important because host-initiated macrophage infiltration into the
implanted TEVG is essential for vascular neo-tissue formation. In 2011, Hibino et al.
analyzed the role of host macrophages in the development of TEVG stenosis51. When
PLLA-P(CL/LA) scaffolds, unseeded or seeded were implanted as infrarenal IVC
interposition grafts in CB57BL/6 wild type mice, the amount of macrophage infiltration
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was directly related to the extent of graft stenosis at 14-days, but inversely proportional to
BM-MNC seeding. It is important to note that macrophages are a heterogeneous subset of
mononuclear cells that are an active part of a host immune response to foreign implanted
grafts53. In an effort to characterize the function of the varying types of macrophages,
they have been divided into phenotypes based on their biological function, surface
markers, and cytokine profile54. These macrophages are often referred to as M1 or M2
cells. M1 macrophages are pro-inflammatory, cytotoxic cells that promote pathogen
killing and chronic inflammation while M2 macrophages are anti-inflammatory cells that
promote tissue remodeling, tissue repair and immunoregulation55. The 2011 study
illustrated that seeded scaffolds express significantly less pro-inflammatory M1
phenotype macrophages than unseeded scaffolds51. It also showed that macrophages
infiltrating patent grafts shift towards the M2 phenotype while those found in stenotic
grafts show increased expression of the M1 phenotype suggesting that scaffold seeding
decreased rates of stenosis by modulating the macrophage response51,56. In the same
study, TEVGs were implanted into mice that were macrophage-depleted following the
application of clodronate liposomes, which cause clodronate-induced apoptosis following
endocytosis by macrophages51,57. These mice had grafts with reduced cellularity,
decreased concentration of DNA per scaffold, absence of luminal endothelial cells as
seen by a lack of vWF staining, absence of smooth muscle cells as evidenced by a lack of
SMA staining, and decreased collagen. These findings suggest that inhibiting
macrophage infiltration into implanted grafts prevents the formation of vascular neotissue
and attest to the importance of macrophage involvement in neo-vessel development. To
certify that this finding was not caused directly by clodronate liposome treatment,
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TEVGs were implanted as infrarenal IVC interposition grafts in CD11b-diptheria toxin
receptor knockout mice that were depleted of macrophages by intraperitoneal injection of
diphtheria toxin. These mice exhibited diminished F4/80 staining, and absent vWF, SMA
and collagen staining. Together these results suggest that lack of macrophage infiltration
prevents adequate neo-vessel formation in TEVGs51.

At this stage our lab had determined the importance of host macrophage infiltration for
neotissue formation and the role of seeded mononuclear cells in recruiting macrophages.
However, the exact molecular mechanism responsible for this recruitment remained
elusive. To determine which molecules may be responsible for early monocyte
(macrophage precursor) recruitment, the cytokine profile of scaffolds seeded with
hBMCs was examined56. While there was a significant increase in the production of
multiple cytokines, there were particularly high levels of monocyte chemotactic protein 1
(MCP-1). In 2000, Salcedo et al. had shown the importance of MCP-1 in angiogenesis,
especially for the chemotaxis of human endothelial cells and an associated inflammatory
response composed primarily of monocytes58. To investigate the isolated effect of MCP1, biodegradable alginate microparticles were constructed and used to encapsulate
recombinant human MCP-156. These microparticles were embedded into scaffolds and
implanted as IVC interposition grafts in SCID/bg mice where they released MCP-1 over
a span of 72 hours. At one week post-implantation, monocyte recruitment was
significantly greater in MCP-1 eluting scaffolds (200 ± 60 monocytes/hpf) compared to
unseeded scaffolds (60 ± 12 monocytes/hpf). At 10 weeks following implantation, all
MCP-1 eluting scaffolds remained patent and histologic analysis showed a monolayer of
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luminal endothelial cells surrounded by smooth muscle cells and abundant collagen
deposition in a pattern identical to that seen in scaffolds seeded with BM-MNCs56.

In a parallel study, Mirensky et al. examined the importance of monocytes in graft
formation59. PGA-P(CL/LA) scaffolds were seeded with 1) heterogeneous BM-MNC, 2)
BM-MNC minus CD14+/CD45+ monocytes, or 3) isolated CD14+/CD45+ monocytes and
implanted as infrarenal IVC interposition grafts in immunocompromised SCID/bg mice.
When grafts were explanted at six months post-implantation, internal diameters were
significantly greater in scaffolds seeded with only monocytes (1.022 ± 0.155 mm)
compared to scaffolds seeded without monocytes (0.771 ± 0.121 mm)59. These
differences allude to the importance of monocytes in the maintenance of long-term graft
patency through the reduction of graft stenosis.

The results of the current study are important for several reasons. First, the presently
accepted methods of BM-MNC isolation rely on density centrifugation, which is labor
and resource intensive, time-consuming, and has significant variability based on operator
technique42. A filter-based isolation method, similar to the one used in this study, was
first used to isolate mononuclear cells from peripheral human blood where it was
extremely effective60. Then it was successfully used to isolate BM-MNCs from human
bone marrow and demonstrate that scaffolds seeded with either the filter-based method or
density centrifugation would develop morphologically equivalent neo-vessels when
implanted as IVC interposition grafts in immune-deficient SCID/bg mice46. As discussed
earlier, however, elements of the host-mediated immune response, specifically infiltrating
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macrophages, are essential for development of a neo-vessel resembling native tissue. In
the present study, autologous BM-MNCs were isolated from wild type mice using filterbased versus density centrifugation methods and then implanted into immune-competent
CB57BL/6 mice. This difference is significant because the host immune system is intact
in these mice and it plays an integral role in the development of endothelial cells, smooth
muscle cells, and collagen in neo-vessels61,62. Our results show that filter-based collection
works just as well in an immunocompetent model as in an immunocompromised model.
These results provide small animal model data that supports the safe and efficacious use
for this vascular graft system in human clinical studies.
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CONCLUSION

In this study a significantly greater number of total cells were isolated using the filterbased method suggesting it is more efficient than density centrifugation at BM-MNCs
isolation. Further, the number of viable cells following filtration and cellular attachment
measured by DNA content after 24 hour incubation of seeded scaffolds suggest the filterbased method is less destructive and damaging to cells than density centrifugation.

These results, as compared with the Ficoll density method of MNC isolation, show no
difference in the biological activity of cells isolated by the filter-based method and no
difference in the TEVGs created from scaffolds subsequently seeded by these cells.
Importantly, the equivalence of the safety and efficacy of the filter versus density
centrifugation based methods of TEVG formation, has been demonstrated in a large
animal model48. Based on the results of this and previous studies, the filter-based method
of BM-MNC isolation from bone marrow for scaffold seeding and the composition of the
tissue in resulting TEVGs can be considered as biologically and structurally similar to
TEVGs formed via the original density centrifugation based method. Since the filterbased method can be fabricated as a closed, sterile, and disposable system that is effective
for scaffold seeding and TEVG formation, it can be utilized commercially as a method
that significantly reduces cost, risk of infection, time required for cell isolation and
removes operator variability. It is important to note that although a manual pipet was
used for scaffold seeding in this study, a fully closed system would require vacuum
seeding method as previously described42. The efficacy of the filter-based method has
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now been established in small and large animal studies using both murine and human
BM-MNCs. As the next step, process improvement studies of the filter-based method
should be conducted in human patients where it has the potential to significantly reduce
time under anesthesia and time in the operating room while the MNCs are collected and
processed. This would substantially reduce both cost and potential patient complications
from prolonged anesthesia exposure and an extended time of surgery. Further, the filterbased method would allow these operations to be performed at many more hospitals
because ISO class 7 clean rooms would no longer be required. Even in large academic
centers with established clean rooms, these facilities are often not in close proximity to
operating rooms and bone marrow may need to be transported between buildings while
an anesthetized patient is waiting on the operating table. This is especially concerning for
pediatric patients. With the ability to extract bone marrow, isolate cells for seeding, seed
the scaffold and implant the graft all within the operating room, the chance of mixing
samples between patients is essentially eliminated. These improvements would expand
the number of patients able to safely and quickly undergo procedures involving TEVG
implantation thus leading to a substantial cost savings and advance in surgical care.
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FIGURES

Figure 1. Neo-vessel formation from bone marrow-derived mononuclear cell (BM-MNC)
seeded biodegradable scaffolds. Seeded BM-MNCs secrete monocyte chemotactic protein 1
(MCP-1) leading to monocyte infiltration. Incoming monocytes release cytokines that promote
the influx of endothelial and smooth muscle cells from adjacent native vessel segments. These
incoming cells create a neotissue on the luminal surface of the scaffold that resembles native
tissue. The original monocytes exit the graft as the scaffold degrades leaving behind a complete
neo-vessel. Reproduced from Roh et al., Ref 56, with permission from PNAS.

35

Figure 2. Closed disposable filter-based seeding system. (1) A 15 mL mixture of extracted
bone marrow plus RPMI-1640 is injected into the elevated sterile bone marrow bag. (2) The
mixture is passed downward through the filter media by gravitational flow, which entraps bone
marrow-derived mononuclear cells (BM-MNCs) through interception. (3) Retained BM-MNCs
are recovered from the filter media by reverse flushing 6 mL of harvest solution (10% dextran
40/saline) through the filter. (4) The retrieved solution is centrifuged at 1500 rpm for 10 minutes.
Figure from Breuer lab.
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Figure 3. Evaluation of bone marrow-derived mononuclear cells (BM-MNCs) following
isolation. Manual cell count was used to determine number of total BM-MNCs and trypan blue
stain was used to define viable BM-MNCs. The filter-based isolation group had significantly
greater total and viable BM-MNCs than the density centrifugation group following evaluation by
the Student’s t test.
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Figure 4. Cell attachment to scaffolds following seeding and incubation. DNA quantification
was utilized to determine BM-MNC attachment to scaffolds following seeding and 24-hour
incubation. The DNA content, used as a measurement of cell attachment, in the filter group was
significantly greater than in the density centrifugation group using Welch’s t test.
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Figure 5. Analysis of TEVG structural parameters. A) Graft patency was defined as a luminal
diameter greater than 50% compared to the pre-implantation graft. There was no significant
difference in graft patency between the filter and density centrifugation groups according to data
analyzed using the Fisher’s exact test. B) Luminal diameter and neointimal thickness did not
differ significantly between TEVGs constructed from either group following evaluation using the
Welch’s t test.
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Figure 6. Macrophage infiltration in TEVGs. Macrophages were counted manually after
staining for F4/80 positive cells in grafts 2 weeks after implantation. There was no significant
difference between the two groups following analysis of data using the Mann-Whitney test.
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Figure 7. Gene expression of macrophage phenotypes in TEVGs. Gene expression was
assessed using the ΔΔ Ct method following real time quantitative reverse transcription
polymerase chain reaction (RT-qPCR). Gene expression of the macrophage marker CD11b
following isolation (upper panel) and 2 weeks after implantation (lower panel) showed no
difference between the filter and density centrifugation methods. In addition, gene expression of
the macrophage M1 phenotype marker iNOS and M2 phenotype marker CD206 was not
significantly different 2 weeks after implantation. This data was analyzed using the Student’s t
test.
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